Aiello Joshua 4

What Happened
Joshua Aiello, Principal Accounting Officer at Orchestra BioMed (OBIO), was granted 70,000 derivative securities reported as an award on February 12, 2026. The Form 4 lists the acquisition price as $0.00 (derivative award), so no cash was paid in this transaction. This is an equity-compensation award (stock options or similar), not an open‑market purchase or sale.

Key Details

• Transaction date: February 12, 2026; Form 4 filed Feb 13, 2026 (reporting timely).
• Reported acquisition: 70,000 shares (derivative award) at $0.00 reported price.
• Shares/ownership after transaction: Not specified in the provided filing excerpt.
• Vesting (per footnote): 25% vest on Feb 12, 2027; the remaining 75% vest in equal installments every three months starting May 12, 2027, subject to continuous service.
• No indication in the filing that any shares were immediately sold or that a 10b5-1 plan, gift, or tax-withholding event applied.

Context
This was a standard equity award to an executive — a compensation event rather than a market trade — and the award vests over time, which is typical for retaining employees. Because this is a derivative grant (options/awards), it does not by itself reflect an immediate buy or sell signal.